The aptamers market size is estimated to be worth $451 million in 2024 and is expected to reach $12,782 million by 2035, growing at CAGR of 36% during the forecast period, till 2035.
Aptamer-based products (therapies and technologies) have offered an effective and alternative way of treatment and diagnosis. In fact, owing to their applicability across a wide range of clinical conditions, such as ocular disorders, oncological disorders and hematological disorders, the demand for such therapies is likely to witness a surge in the foreseen future. In order to cater to such higher demand, drug developers are actively seeking to enter into collaborations with contract manufacturers.
It is worth noting that, since several aptamer-based therapeutic candidates are currently being investigated in clinical stages of development, the clinical demand is estimated to be significantly higher, as compared to the commercial demand for such therapeutic products.
Start-Ups are spearheading the innovation in this domain; our proprietary benchmarking analysis, based on a variety of parameters, highlights the leading players. During our secondary research, we were able to identify 22 (established after 2010; having 1-200 employees) aptamer-based therapeutics providers. Presently, most of the start-ups engaged in this domain are based in North America, followed by those located in Asia-Pacific.
Foreseeing lucrative returns, many public and private investors have made investments worth USD 1.3 billion since 2016; the funding activity is well distributed across geographical regions.
During our research, we came across funding instances focused on aptamers, during the period 2016-2021, which amounted to a total of more than USD 1.3 billion. there has been a steady increase in the funding activity during the given time period. It is worth noting that maximum number of funding instances focused on aptamers were reported in 2020.
Aptamers have gained a lot of momentum in the past decade. It is worth highlighting that in 2005, Macugen became the first and the only USFDA approved aptamer drug for treating age-related macular degeneration (AMD). It has been reported that more than 15 million people in the US suffer from AMD alone with 200,000 cases annually across North America. This indicates a high unmet need of patients thus, paving a way for aptamer-based solutions due to their advantages over traditional antibody-based therapies. This has led to rapid developments in the domain which can be attributed to various factors, such as number in the number of clinical trials, increased awareness about advantages offered by aptamers as compared to antibodies, rise in the investment in the pharmaceutical research and development, along with rise in prevalence of chronic and rare diseases have contributed to the increase in the demand for aptamers-based therapeutics and diagnostic solutions. Aptamers are developed through the SELEX process and over the years these have become primary tools for aptamer synthesis.
Over the past three decades, since the invention of SELEX by Larry Gold and Jack William in the 1990, the technology has seen several modifications to streamline and standardized aptamer-isolation process. These modifications substantially enhance efficiency / optimization to yield best possible aptamer or reduce the duration of the process. Other noteworthy developments in modifications of aptamers, include the addition of functional units of non-nucleic origin and nucleotide modifications, which further improves aptamer performance.
Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/medical-robotics-market.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/
